Pharmacogenomics IND EXEMPT SNP Clinical Study - Crizotinib and Single Nucleotide Polymorphisms - Trial NCT06062810
Access comprehensive clinical trial information for NCT06062810 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair and is currently Not yet recruiting. The study focuses on Non-Small Cell Lung Cancer. Target enrollment is 600 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Medicine Invention Design, Inc
Timeline & Enrollment
Phase 2/3
Oct 28, 2023
Dec 28, 2024
Primary Outcome
Measure and Report Crizotinib oncology drug target ALK SNP Genotypes which are effectiveness-associated.,Measure and Report Crizotinib oncology drug target CYP4503A SNP Genotypes which are risk associated.
Summary
Explore the relationship between drug target ALK gene single nucleotide polymorphisms and
 XALKORI - Crizotinib therapeutic-effects in patients with non-small cell lung cancer, based
 on Oxford precisely sequencing drug targets' genes.
 
 Explore the relationship between drug target CYP4503A gene single nucleotide polymorphisms
 and XALKORI - Crizotinib side-effects in patients with non-small cell lung cancer, based on
 Oxford precisely sequencing drug targets' genes.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06062810
Non-Device Trial